Ticker League

Cash on Hand for Alnylam Pharmaceuticals (ALNY)

As of · Reported

Metric

Latest period

$3.01B

YoY change

+7.9%

5Y CAGR

+9.2%

Peak year (2025)

$2.91B

Cash on Hand history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: $2.91B

Cash on Hand growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: +7.9%

Cash on Hand history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

  • 2025$2.91B+7.9%
  • 2024$2.69B+10.5%
  • 2023$2.44B+11.3%
  • 2022$2.19B-10.0%
  • 2021$2.44B+29.9%
  • 2020$1.87B+22.0%
  • 2019$1.54B+41.7%
  • 2018$1.08B-35.9%
  • 2017$1.69B+169.7%
  • 2016$626.80M-42.0%
  • 2015$1.08B+55.1%
  • 2014$696.69M+183.4%
  • 2013$245.87M+100.2%
  • 2012$122.81M-16.1%
  • 2011$146.40M-37.2%
  • 2010$233.13M-17.2%
  • 2009$281.40M-34.6%
  • 2008$430.39M+10.4%
  • 2007$389.95M+79.5%
  • 2006$217.26M+171.6%
  • 2005$80.00M+73.7%
  • 2004$46.05M+98.5%
  • 2003$23.19M+49.9%
  • 2002$15.48M—

Cash on Hand values are taken from Alnylam Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Cash on Hand at Alnylam Pharmaceuticals (ALNY)

According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $3.01B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Alnylam Pharmaceuticals (ALNY) most recent annual cash and short-term investments stands at $2.91B (2025) – grew 7.9% year-over-year.

Alnylam Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +9.2%, sustaining 3 straight years of year-over-year growth.

2025 marks the peak cash and short-term investments at $2.91B, with the historical low of $15.48M recorded in 2002.

Alnylam Pharmaceuticals Cash on Hand by Year

Alnylam Pharmaceuticals Cash on Hand 2025: $2.91B

Alnylam Pharmaceuticals posted cash and short-term investments of $2.91B in 2025, grew 7.9% from 2024. This figure represents the highest annual value in the available history.

Alnylam Pharmaceuticals Cash on Hand 2024: $2.69B

In 2024, Alnylam Pharmaceuticals reported cash and short-term investments of $2.69B, grew 10.5% from 2023.

Alnylam Pharmaceuticals Cash on Hand 2023: $2.44B

Alnylam Pharmaceuticals cash and short-term investments in 2023 was $2.44B, grew 11.3% from 2022.

Alnylam Pharmaceuticals Cash on Hand 2022: $2.19B

2022's cash and short-term investments for Alnylam Pharmaceuticals came in at $2.19B, declined 10.0% below 2021.

Alnylam Pharmaceuticals Cash on Hand 2021: $2.44B

Alnylam Pharmaceuticals cash and short-term investments in 2021 was $2.44B.

See more financial history for Alnylam Pharmaceuticals (ALNY).

Sector peers by Cash on Hand

Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest cash and short-term investments

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return